Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of URGN is 35 and suggests 66% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell